Curis Announces Positive Safety, Tolerability and Pharmacokinetic Data in Ongoing Phase 1 Study of Fimepinostat in Combination with Venetoclax

Stock Information for Curis Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Curis Inc.

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Curis to Present at Upcoming Healthcare Conferences in April
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Curis, Inc. (NASDAQ: CRIS)
Curis Provides Fourth Quarter 2023 Business Update
Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study
Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.